scholarly journals MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review

2021 ◽  
pp. 1-10
Author(s):  
Ludger Klimek ◽  
William E. Berger ◽  
Jean Bousquet ◽  
Paul K. Keith ◽  
Peter Smith ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Fluticasone Propionate ◽  
Treatment Options ◽  
Symptomatic Disease ◽  
Intranasal Corticosteroids ◽  
Need For Treatment ◽  
Ocular Symptoms ◽  
Symptom Complex

Allergic rhinitis (AR) is prevalent, and many patients present with moderate-to-severe symptomatic disease. The majority of patients are not satisfied with their AR treatment, despite the use of concurrent medications. These gaps underscore the need for treatment with more effective options for moderate-to-severe AR. The authors’ objective was to review systematically the efficacy and safety of MP-AzeFlu for the treatment of AR. The primary outcomes studied were nasal, ocular, and total symptoms. Other outcomes included time to onset and of AR control, quality of life, and safety. Searches of PubMed and Cochrane databases were conducted on May 14, 2020, with no date restrictions, to identify publications reporting data on MP-AzeFlu. Clinical studies of any phase were included. Studies were excluded if they were not in English, were review articles, did not discuss the safety and efficacy of MP-AzeFlu for AR symptoms. Treatment of AR with MP-AzeFlu results in effective, sustained relief of nasal and ocular symptoms, and faster onset and time to control compared with intranasal azelastine or fluticasone propionate. Long-term use of MP-AzeFlu was safe, with benefits in children, adults, and adults aged ≥65 years. Other treatment options, including fluticasone propionate and azelastine alone or the combination of intranasal corticosteroids and oral antihistamine, do not provide the same level of efficacy as MP-AzeFlu in terms of rapid and sustained relief of the entire AR symptom complex. Furthermore, MP-AzeFlu significantly improves patient quality of life. MP-AzeFlu is a currently available combination that may satisfy all these patient needs and expectations.

scholarly journals Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Eli O. Meltzer ◽  
Nelson Augusto Rosario ◽  
Hugo Van Bever ◽  
Luiz Lucio
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Second Generation ◽  
Safety Data ◽  
Negative Effects ◽  
Intranasal Corticosteroids ◽  
Ocular Symptoms ◽  
Cardiovascular Side Effects ◽  
Favorable Safety

AbstractAllergic rhinitis (AR) is the most common undiagnosed chronic condition in children. Moderate/severe AR symptoms significantly impair quality of life, and cause sleep disruption, absenteeism and decreased productivity. Additionally, untreated AR predisposes children to asthma and other chronic conditions. Although intranasal corticosteroids are the most effective pharmacologic treatment for AR, oral antihistamines are often preferred. First-generation antihistamines may be chosen to relieve AR symptoms as they are inexpensive and widely available; however, they cause sedative and cardiovascular negative effects due to poor receptor selectivity. Therefore, second-generation antihistamines were developed to reduce adverse effects while retaining efficacy. There are fewer clinical trials in children than adults, therefore, efficacy and safety data is limited, particularly in children under 6 years, highlighting the need to generate these data in young children with AR. Fexofenadine, a highly selective second-generation antihistamine, effectively alleviates symptoms of AR, is non-sedating due to decreased blood–brain barrier permeability, and is devoid of cardiovascular side effects. Importantly, fexofenadine relieves the ocular symptoms of allergic conjunctivitis, which occur concomitantly with AR, improving quality of life. Overall, fexofenadine displays a favorable safety profile and results in greater treatment satisfaction in children compared with other second-generation antihistamines. This review aimed to evaluate and compare the safety and efficacy of fexofenadine with other available first- and second-generation antihistamines in children with AR.

Allergic Rhinitis

2021 ◽  
Author(s):  
Sonya Marcus
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Congestion ◽  
Treatment Options ◽  
The United States ◽  
Subcutaneous Immunotherapy ◽  
Allergy Testing ◽  
Intranasal Corticosteroids ◽  
Substantial Economic Burden ◽  
Key Words Allergic Rhinitis

Allergic rhinitis is a common condition that affects 10-40% of adults in the United States annually. It has a significant impact on patient quality of life and poses a substantial economic burden on society. Knowledge regarding accurate diagnosis, testing and treatment options are important in the management of this prevalent condition. Treatment options include allergen avoidance, pharmacotherapy and allergy immunotherapy. This review contains 7 figures, 6 tables and 28 references. Key words: allergic rhinitis, rhinorrhea, nasal congestion, intranasal corticosteroids, antihistamines, skin prick allergy testing, intradermal allergy testing, subcutaneous immunotherapy, sublingual immunotherapy, anaphylaxis

Intranasal Ciclesonide in Allergic Rhinitis

2010 ◽  
Vol 2 ◽  
pp. CMT.S4120
Author(s):  
Harissios Vliagoftis
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Indirect Costs ◽  
Pharmacokinetic Profile ◽  
Improve Quality ◽  
Perennial Allergic Rhinitis ◽  
Direct And Indirect Costs ◽  
Intranasal Corticosteroids ◽  
Very High

Allergic rhinitis affects more than 20% and is responsible for very high direct and indirect costs. Nasal corticosteroids are the principle pharmaceutical option for the treatment of allergic rhinitis. They are more effective than all other therapeutic options and in addition to improving symptoms of allergic rhinitis they also improve quality of life in patients suffering from allergic rhinitis. There are many intranasal corticosteroids approved for the treatment of allergic rhinitis in pediatric and adult populations. Ciclesonide has shown so far a very good safety and pharmacokinetic profile and is effective for treatment of symptoms in both seasonal and perennial allergic rhinitis. This review summarizes the studies describing these effects of intranasal ciclesonide.

Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis

Allergy ◽  
2002 ◽  
Vol 57 (7) ◽  
pp. 586-591 ◽  
Author(s):  
G. Ciprandi ◽  
W. G. Canonica ◽  
M. Grosclaude ◽  
J. Ostinelli ◽  
G. G. Brazzola ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Fluticasone Propionate ◽  
Seasonal Allergic Rhinitis ◽  
Controlled Study

Leukotriene Receptor Antagonist Addition to H1-Antihistamine Is Effective for Treating Allergic Rhinitis: A Systematic Review and Meta-analysis

2019 ◽  
Vol 33 (5) ◽  
pp. 591-600 ◽  
Author(s):  
Kachorn Seresirikachorn ◽  
Wirach Chitsuthipakorn ◽  
Dichapong Kanjanawasee ◽  
Likhit Khattiyawittayakun ◽  
Kornkiat Snidvongs
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Receptor Antagonist ◽  
Meta Analysis ◽  
Leukotriene Receptor Antagonist ◽  
Ocular Symptoms ◽  
Nasal Symptoms ◽  
Subgroup Analyses ◽  
Leukotriene Receptor

Background Histamine and leukotriene are released after being triggered by allergen exposure. The combination of leukotriene receptor antagonist (LTRA) and H1-antihistamine (AH) is utilized to control the allergic rhinitis (AR) symptoms after the failure of either AH or LTRA. Objective This study aimed to investigate the effects of the combination of H1-antihistamine and leukotriene receptor antagonist (AH-LTRA) in patients with AR. Methods Randomized controlled trials studying the effects of AH-LTRA versus AH alone on rhinoconjuncitivits symptoms in patients with AR were included. Data were pooled for meta-analysis. The outcomes were nasal symptoms, ocular symptoms, disease-specific quality of life, and adverse events. Meta-analyses were performed to compare the outcomes between AH-LTRA and AH. Subgroup analyses by AR subtype, asthma, and pediatric patients were performed. Results Fourteen studies (3271 participants) met the inclusion criteria. The results favored the effects of AH-LTRA on (1) composite nasal symptom score (standardized mean difference [SMD]: −0.20; 95% confidence interval [CI]: −0.36, −0.03), (2) rhinorrhea (SMD: −0.14; 95% CI: −0.27, −0.02), and (3) sneezing (SMD: −0.15; 95% CI: −0.27, −0.02). Subgroup analyses revealed that results favored the effects of AH-LTRA for perennial AR (SMD: −0.57; 95% CI: −0.87, −0.26) but not in the seasonal AR subgroup (SMD: −0.09; 95% CI: −0.21, 0.04), P = .004. There were no differences between AH-LTRA and AH on nasal obstruction, itching, ocular symptoms, Rhinoconjunctivitis Quality of life Questionnaire and adverse events. Due to limited number of included studies, effects on asthma and pediatric subgroups could not be assessed. Conclusion For controlling rhinoconjunctivitis symptoms in patients with AR, AH-LTRA provided greater beneficial effects on composite nasal symptoms, rhinorrhea, and sneezing compared to AH alone. These effects were shown in patients with perennial AR.

The Effect of Intranasal Corticosteroids on Asthma Control and Quality of Life in Allergic Rhinitis with Mild Asthma

2010 ◽  
Vol 48 (1) ◽  
pp. 41-47 ◽  
Author(s):  
Nicola Scichilone ◽  
Rita Arrigo ◽  
Alessandra Paternò ◽  
Roberta Santagata ◽  
Silvana Impellitteri ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Asthma Control ◽  
Mild Asthma ◽  
Intranasal Corticosteroids

Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a randomised, double-blind, placebo-controlled study

2014 ◽  
Vol 128 (3) ◽  
pp. 242-248 ◽  
Author(s):  
B-S Goh ◽  
M I M Ismail ◽  
S Husain
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Placebo Group ◽  
Fluticasone Propionate ◽  
Nasal Spray ◽  
Life Assessment ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

AbstractObjective:This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis.Methods:A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales.Results:A total of 128 patients (aged 13–51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group.Conclusion:The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.

Sign in / Sign up

Export Citation Format

Share Document